TY - JOUR
T1 - Immobilized FhuD2 Siderophore-Binding Protein Enables Purification of Salmycin Sideromycins from Streptomyces violaceus DSM 8286
AU - Rivera, Gerry Sann M.
AU - Beamish, Catherine R.
AU - Wencewicz, Timothy A.
N1 - Funding Information:
We thank Dr. Brad Evans at the Proteomics & Mass Spectrometry Facility at the Donald Danforth Plant Science Center, St. Louis, MO, for assistance with the acquisition of the QTRAP LC-MS/MS spectra (supported by the National Science Foundation under Grant No. DBI-0521250). We thank Prof. John-Stephen Taylor (WUSTL, Dept. of Chemistry) for assistance with fluorescence quenching studies. We thank Prof. Marvin J. Miller (University of Notre Dame, Dept. of Chemistry and Biochemistry) for providing samples of SFO and Dan through a material transfer agreement (MTA). We thank Prof. Michael Gross and Ming Cheng (WUSTL, Dept. of Chemistry; NIH P41GM103422) for assistance with ESI-MS analysis of N-His6-FhuD2Δ24. Research was supported by start-up funds from Washington University in St. Louis, Oak Ridge Associated Universities via a Ralph E. Powe Junior Faculty Enhancement Award FY2014-215, and NSF CAREER Award 1654611 to T.A.W.
Publisher Copyright:
© 2018 American Chemical Society.
PY - 2018/5/11
Y1 - 2018/5/11
N2 - Siderophores are a structurally diverse class of natural products common to most bacteria and fungi as iron(III)-chelating ligands. Siderophores, including trihydroxamate ferrioxamines, are used clinically to treat iron overload diseases and show promising activity against many other iron-related human diseases. Here, we present a new method for the isolation of ferrioxamine siderophores from complex mixtures using affinity chromatography based on resin-immobilized FhuD2, a siderophore-binding protein (SBP) from Staphylococcus aureus. The SBP-resin enabled purification of charge positive, charge negative, and neutral ferrioxamine siderophores. Treatment of culture supernatants from Streptomyces violaceus DSM 8286 with SBP-resin provided an analytically pure sample of the salmycins, a mixture of structurally complex glycosylated sideromycins (siderophore-antibiotic conjugates) with potent antibacterial activity toward human pathogenic Staphylococcus aureus (minimum inhibitory concentration (MIC) = 7 nM). Siderophore affinity chromatography could enable the rapid discovery of new siderophore and sideromycin natural products from complex mixtures to aid drug discovery and metabolite identification efforts in a broad range of therapeutic areas.
AB - Siderophores are a structurally diverse class of natural products common to most bacteria and fungi as iron(III)-chelating ligands. Siderophores, including trihydroxamate ferrioxamines, are used clinically to treat iron overload diseases and show promising activity against many other iron-related human diseases. Here, we present a new method for the isolation of ferrioxamine siderophores from complex mixtures using affinity chromatography based on resin-immobilized FhuD2, a siderophore-binding protein (SBP) from Staphylococcus aureus. The SBP-resin enabled purification of charge positive, charge negative, and neutral ferrioxamine siderophores. Treatment of culture supernatants from Streptomyces violaceus DSM 8286 with SBP-resin provided an analytically pure sample of the salmycins, a mixture of structurally complex glycosylated sideromycins (siderophore-antibiotic conjugates) with potent antibacterial activity toward human pathogenic Staphylococcus aureus (minimum inhibitory concentration (MIC) = 7 nM). Siderophore affinity chromatography could enable the rapid discovery of new siderophore and sideromycin natural products from complex mixtures to aid drug discovery and metabolite identification efforts in a broad range of therapeutic areas.
KW - affinity chromatography
KW - desferrioxamine B
KW - drug delivery
KW - iron transport
KW - metal chelation therapy
KW - siderophore-antibiotic conjugate
UR - http://www.scopus.com/inward/record.url?scp=85046905669&partnerID=8YFLogxK
U2 - 10.1021/acsinfecdis.8b00015
DO - 10.1021/acsinfecdis.8b00015
M3 - Article
C2 - 29460625
AN - SCOPUS:85046905669
SN - 2373-8227
VL - 4
SP - 845
EP - 859
JO - ACS Infectious Diseases
JF - ACS Infectious Diseases
IS - 5
ER -